FDA FINALLY Recalls Weight Loss Drug Belviq As Cancer Links Increase

Via America’s Lawyer: The weight loss pill, Belviq, pulled from the shelves by the FDA due to an increased risk of cancer. Now other side effects are coming to light as patients are filling more complaints. Attorney Madeline Pendley joins Mike Papantonio to discuss more.

Find out fore about Belviq dangers and lawsuits at

Become a member today!

Support us by becoming a monthly patron on Patreon, and help keep progressive media alive!

Find our merchandise at Teespring

Spread the word! LIKE and SHARE this video or leave a comment to help direct attention to the stories that matter. And SUBSCRIBE to stay connected with Ring of Fire's video content!

Support Ring of Fire by subscribing to our YouTube channel

Be sociable! Follow us on:

Follow more of our stories at

Subscribe to our podcast

*This transcript was generated by a third-party transcription software company, so please excuse any typos.

A weight loss pill pulled from the shelves by the FDA due to an increased risk of cancer. Now, other side effects are coming to light as patients are filing more complaints. We're joined by Madeline Pendley associate attorney here at Levin Papantonio, to talk about this case. Maddy, we've seen so many cases with weight loss. We saw Fen-Phen thousands of people, literally thousands, became ill. Hundreds of them died.

Right.

And now the FDA let this thing go through and all this thing is just another way to tell women, hey, lose weight, take this pill and everything's going to be okay. Give me your take on it.

So Belviq like you mentioned, it operates almost exactly the same way as Fen-Phen, it's a serotonin 2C receptor blocker, means it tells the brain we're not hungry anymore. You can eat less, feel fuller faster and stuff like that. The problem is this drug has reported an increased risk of cancer development, as well as other side effects like mood altering issues like depression and mood swings, dizziness, fatigue and so on.

Right. Well, you know, what's interesting about this. They, they did a study on this, right?

Yeah.

They weren't looking for cancer.

No.

They were trying to say there was a complaint that, you know, people were dying from heart problems.

Right.

And they're saying, trying to say, well, this, this doesn't cause heart problems. So they did this study for the, FDA demanded it, finally did their job and they find out, well, no, it doesn't cause heart problems, but it'll kill you with cancer. What kind of cancers?

Typically it's lung, pancreatic and colorectal cancers and what's so interesting and you touched on it. These companies initially submitted their drug to the FDA in 2009 and the FDA blocked it. Like, nope, no way. You guys don't have a good handle on the side effects that come with this drug. The companies resubmitted it in 2012 and FDA hesitantly was like, okay, you can give it to a limited group of people, but you have to do long-term studies on this to figure out the side effects and these companies did. But in the meantime, this company was actually blocked in Europe in 2013, specifically for increased risk of tumor development in the animal studies. So this, these both companies Arena and Eisai had this information about the tumors in animals in 2013, didn't tell the FDA and did not disclose it to the public.

Interesting, the FDA has access to what's going on around the world.

Of course.

Okay. It's not like we're a bunch of, well, maybe we are a bunch of bumpkins. The FDA certainly looks like bumpkins.

Appears to be, yeah.

Most of the time. But it's not like, if you do a study in Europe, the, the agency over there said, yeah, we looked at this, there's tumor growth. There's cancer.

100%.

Comes off the market over there. These idiots with the FDA say, oh, we don't have enough information.

Right.

People are taking this stuff like candy to lose weight, just like they did Fen-Phen with all these women died unnecessarily, right?

Right. And like you said, the FDA one, can communicate with, with Europe, they're allowed to do that. They'll get that information. But it also raises the question. Why could Europe's basically FDA figure this out and ours couldn't'? They have the same information, the same disclosure from the companies and our company raises their hand and can't figure it out.

Here's the difference. FDA, you can't give a politician money.

Right.

#rof #trofire #theringoffire #progressivenews